Zinc Finger Protein ZBTB20 protects against cardiac remodelling post‐myocardial infarction via ROS‐TNFα/ASK1/JNK pathway regulation

• Published in: Journal of cellular and molecular medicine 2020-11, Vol.24 (22), p.13383-13396
• Main Authors: Li, Fangfang, Yang, Yiming, Xue, Chuanyou, Tan, Mengtong, Xu, Lu, Gao, Jianbo, Xu, Luhong, Zong, Jing, Qian, Wenhao
• Format: Article
• Language: English
• Subjects: Antibodies; Apoptosis; ASK1/JNK1/2; cardiac remodelling; Cardiomyocytes; Cell cycle; Congestive heart failure; Coronary vessels; Dehydrogenases; Fibrosis; Gene expression; Heart attacks; Hypertrophy; Hypoxia; Infrared imaging systems; JNK protein; Kinases; Laboratory animals; MAP kinase; Morphology; Myocardial infarction; Original; Proteins; Signal transduction; Surgery; Transfection; Tumor necrosis factor-TNF; Tumor necrosis factor-α; Tumors; Veins & arteries; Ventricle; ZBTB20; Zinc finger proteins
• ISSN: 1582-1838; 1582-4934
• DOI: 10.1111/jcmm.15961

This study aims to determine the efficacy of Zinc finger protein ZBTB20 in treatment of post‐infarction cardiac remodelling. For this purpose, left anterior descending (LAD) ligation was operated on mice to induce myocardial infarction (MI) with sham control group as contrast and adeno‐associated virus (AAV9) system was used to deliver ZBTB20 to mouse heart by myocardial injection with vehicle‐injected control group as contrast two weeks before MI surgery. Then four weeks after MI, vehicle‐treated mice with left ventricular (LV) remodelling underwent deterioration of cardiac function, with symptoms of hypertrophy, interstitial fibrosis, inflammation and apoptosis. The vehicle‐injected mice also showed increase of infarct size and decrease of survival rate. Meanwhile, the ZBTB20‐overexpressed mice displayed improvement after MI. Moreover, the anti‐apoptosis effect of ZBTB20 was further confirmed in H9c2 cells subjected to hypoxia in vitro. Further study suggested that ZBTB20 exerts cardioprotection by inhibiting tumour necrosis factor α/apoptosis signal‐regulating kinase 1 (ASK1)/c‐Jun N‐terminal kinase 1/2 (JNK1/2) signalling, which was confirmed by shRNA‐JNK adenoviruses transfection or a JNK activator in vitro as well as ASK1 overexpression in vivo. In summary, our data suggest that ZBTB20 could alleviate cardiac remodelling post‐MI. Thus, administration of ZBTB20 can be considered as a promising treatment strategy for heart failure post‐MI. Significance Statement: ZBTB20 could alleviate cardiac remodelling post‐MI via inhibition of ASK1/JNK1/2 signalling.